Pulmonx Co. (NASDAQ:LUNG – Get Free Report) Director Glendon E. French III sold 20,000 shares of Pulmonx stock in a transaction that occurred on Thursday, October 17th. The stock was sold at an average price of $6.52, for a total transaction of $130,400.00. Following the transaction, the director now directly owns 1,091,974 shares in the company, valued at $7,119,670.48. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Pulmonx Price Performance
LUNG stock opened at $6.13 on Thursday. The stock has a 50-day moving average price of $7.31 and a two-hundred day moving average price of $7.34. Pulmonx Co. has a 1 year low of $5.46 and a 1 year high of $14.84. The stock has a market cap of $237.94 million, a PE ratio of -3.98 and a beta of 0.64. The company has a current ratio of 8.97, a quick ratio of 7.92 and a debt-to-equity ratio of 0.37.
Pulmonx (NASDAQ:LUNG – Get Free Report) last announced its earnings results on Wednesday, July 31st. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.02. Pulmonx had a negative return on equity of 50.79% and a negative net margin of 75.56%. The business had revenue of $20.78 million for the quarter, compared to analyst estimates of $20.23 million. Equities analysts forecast that Pulmonx Co. will post -1.64 EPS for the current fiscal year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Analysis on Pulmonx
Institutional Inflows and Outflows
Hedge funds have recently added to or reduced their stakes in the business. Squarepoint Ops LLC grew its holdings in shares of Pulmonx by 261.2% in the 2nd quarter. Squarepoint Ops LLC now owns 144,409 shares of the company’s stock valued at $916,000 after acquiring an additional 104,432 shares in the last quarter. Sei Investments Co. increased its position in shares of Pulmonx by 2.5% during the 1st quarter. Sei Investments Co. now owns 72,626 shares of the company’s stock worth $673,000 after purchasing an additional 1,800 shares during the last quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in shares of Pulmonx by 7.0% during the 2nd quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A. now owns 1,059,018 shares of the company’s stock worth $6,714,000 after purchasing an additional 69,595 shares in the last quarter. XTX Topco Ltd acquired a new stake in shares of Pulmonx in the 2nd quarter valued at approximately $222,000. Finally, Renaissance Technologies LLC grew its stake in shares of Pulmonx by 13.1% in the second quarter. Renaissance Technologies LLC now owns 301,410 shares of the company’s stock valued at $1,911,000 after buying an additional 34,800 shares in the last quarter. Institutional investors own 91.04% of the company’s stock.
Pulmonx Company Profile
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Featured Stories
- Five stocks we like better than Pulmonx
- EV Stocks and How to Profit from Them
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.